Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Allakos Inc (ALLK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,883,225
  • Shares Outstanding, K 43,124
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,540 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 11.22

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.49
  • Number of Estimates 2
  • High Estimate -0.47
  • Low Estimate -0.50
  • Prior Year -4.17
  • Growth Rate Est. (year over year) +88.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.81 +23.85%
on 05/02/19
45.00 -1.44%
on 05/22/19
+6.23 (+16.34%)
since 04/24/19
3-Month
34.58 +28.25%
on 04/18/19
45.00 -1.44%
on 05/22/19
+6.67 (+17.70%)
since 02/22/19

Most Recent Stories

More News
Allakos Reports First Quarter 2019 Financial Results

Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the first quarter ended March...

ALLK : 44.35 (+1.56%)
Allakos Announces Positive Results with AK002 in Patients with Severe Allergic Conjunctivitis

-- Substantial reduction of patient reported symptoms and physician assessed signs and symptoms --

ALLK : 44.35 (+1.56%)
Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today reported financial results for the fourth quarter and full year...

ALLK : 44.35 (+1.56%)
Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive multiple dose Phase 1 results in patients...

ALLK : 44.35 (+1.56%)
Allakos Enters Oversold Territory

Allakos Inc. (ALLK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

ALLK : 44.35 (+1.56%)
Allakos to Host Investor Day on February 19 in New York City

Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 starting...

ALLK : 44.35 (+1.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade ALLK with:

Business Summary

Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based in CA, United States.

See More

Key Turning Points

2nd Resistance Point 45.81
1st Resistance Point 45.08
Last Price 44.35
1st Support Level 43.49
2nd Support Level 42.63

See More

52-Week High 65.48
Fibonacci 61.8% 50.40
Fibonacci 50% 45.74
Last Price 44.35
Fibonacci 38.2% 41.08
52-Week Low 26.00

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar